ELEKTA ANNOUNCES FIRST TWO CLINICAL SITES USING VMAT CANCER TREATMENT CAPABILITY

ELEKTA ANNOUNCES FIRST TWO CLINICAL SITES USING VMAT CANCER TREATMENT CAPABILITY

PRESS RELEASE	
Stockholm, Sweden, January 18, 2008

Elekta, a world leader in clinical solutions for radiation therapy and
radiosurgery, announced today that two sites are utilizing Elekta technology to
implement clinical treatments with Volumetric Modulated Arc Therapy (VMAT)*.
With the recent CE designation of VMAT in Europe, the way has been cleared for
The Royal Marsden Hospital in Sutton, UK and General Hospital Vienna in Austria
to treat cancer using Elekta's VMAT solution.

VMAT is a significant improvement to existing advanced radiation therapy
techniques, often referred to as IMRT (Intensity Modulated Radiation Therapy)
and offers a faster alternative to helical tomotherapy. With Elekta's VMAT
technology, the target continuously is irradiated while the source of the beam
is rotated around the patient in single or multiple arcs. By simultaneously
controlling gantry position, gantry speed, leaves of the multi-leaf collimator
(MLC), collimator angle and dose rate, a highly conformal dose distribution is
created in significantly less time than with today's techniques. With VMAT from
Elekta, a treatment session typically can be conducted in five minutes or less,
including true 3D imaging to secure the location of the target.

“VMAT is a very promising technique,” says Dietmar Georg, Ph.D., head of the
Division of Medical Radiation Physics, Department of Radiotherapy, Medical
University Vienna/General Hospital Vienna. “The rotational therapy and intensity
modulation results in improved dose distribution and high conformality for
optimal sparing of normal tissue.” Using VMAT, Dr. Georg expects to see a more
efficient workflow and faster treatments for patients receiving advanced
radiotherapy. 

Jim Warrington, head of Radiotherapy Physics at The Royal Marsden Hospital,
says, “With the potential to produce megavoltage X-ray treatments of the highest
quality and efficiency available, we anticipate VMAT will offer us greater
flexibility as a radiotherapy treatment option.” 

Both sites have installed the necessary system updates, and are eagerly
anticipating the first VMAT treatments by the end of January.

Elekta leads the way with dynamic VMAT package

Elekta's solution for VMAT treatments is a complete package that includes
MOSAIQ™, an image-enabled oncology Electronic Medical Records (EMR) system that
supports each member of the cancer care team. The package also contains ERGO++
the first treatment planning system to employ inverse-planning techniques for
rotational IMRT. When combined with existing digital linear accelerators, this
system provides a simple, innovative solution for clinical VMAT cancer
treatment.

As VMAT technology becomes the new standard in cancer care, Elekta continues to
lead the way with advanced solutions for treating serious disease.






* Elekta Volumetric Intensity Modulated Arc Therapy (VMAT) is pending regulatory
approvals in certain markets, including 510(k) clearance in the US, and is not
yet for commercial sale in the US


******

For further information, please contact:

Media inquiries: Michelle Lee, PR and Advertising Manager, Tel: +1 770-670-2447,
 email: michelle.lee@elekta.com

Investor inquiries: Peter Ejemyr, Group VP Corporate Communications, Tel: +46
733 611 000 (mobile), e-mail: peter.ejemyr@elekta.com

Product inquiries: Peter J. Gaccione, Vice President, Global Marketing, Tel: +1
770 670 2380, email: peter.gaccione@elekta.com

About Elekta

Elekta is an international medical technology group, providing oncologists,
radiation therapists, neurosurgeons and many other medical specialists with
state of the art tools to fight serious disease.

Elekta provides advanced clinical solutions, comprehensive management and
information systems as well as services for improved cancer care and management
of brain disorders. 

Elekta's systems and solutions are used in over 4,500 hospitals around the
world. Clinical and information management solutions include, among others,
Leksell Gamma Knife® for non-invasive treatment of brain disorders, Elekta
Axesse™ and Elekta Synergy® for stereotactic and image guided radiation therapy
and radiosurgery as well as the MOSAIQ™ suite of software for image-enabled EMR
and efficient management of clinical and patient data.

With over 2,000 employees globally, the corporate headquarter is located in
Stockholm, Sweden and the company is listed on the Nordic Exchange under the
ticker EKTAb. More information about Elekta can be found at www.elekta.com.